NewAmsterdam Pharma Company N.V.
General ticker "NAMSW" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.6B (TTM average)
NewAmsterdam Pharma Company N.V. follows the US Stock Market performance with the rate: 40.3%.
Estimated limits based on current volatility of 3.1%: low 17.57$, high 18.70$
Factors to consider:
- Total employees count: 17 as of 2022
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [8.45$, 19.61$]
- 2025-12-31 to 2026-12-31 estimated range: [6.29$, 15.34$]
Short-term NAMSW quotes
Long-term NAMSW plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $102.69MM | $14.09MM | $45.56MM |
| Operating Expenses | $106.25MM | $197.06MM | $221.85MM |
| Operating Income | $-3.56MM | $-182.97MM | $-176.29MM |
| Non-Operating Income | $-19.08MM | $6.06MM | $-65.31MM |
| Interest Expense | $0.29MM | $6.80MM | $0.00MM |
| R&D Expense | $86.74MM | $159.42MM | $151.41MM |
| Income(Loss) | $-22.63MM | $-176.91MM | $-241.60MM |
| Taxes | $0.00MM | $0.03MM | $-0.00MM |
| Net Income(Loss)* | $-22.63MM | $-176.94MM | $-241.60MM |
| Stockholders Equity | $430.07MM | $288.39MM | $757.50MM |
| Assets | $478.50MM | $347.10MM | $864.62MM |
| Operating Cash Flow | $10.66MM | $-141.22MM | $-158.56MM |
| Capital expenditure | $0.22MM | $0.02MM | $0.67MM |
| Investing Cash Flow | $-0.22MM | $-0.02MM | $-62.85MM |
| Financing Cash Flow | $391.90MM | $8.91MM | $659.51MM |
| Earnings Per Share** | $-1.19 | $-2.15 | $-2.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.